Recently there has been much interest in the potential for exploring new therapeutic uses for existing drugs, in part, because existing medications are relatively inexpensive and have known side effect profiles, according to Cardwell. This study investigated whether lung cancer patients who received statins had improved cancer outcomes.
Author Chris Cardwell, PhD, at Queen’s University Belfast in Northern Ireland and colleagues used data from nearly 14,000 patients newly diagnosed with lung cancer between 1998 and 2009 from English cancer registry data.
Among patients who survived at least six months after a diagnosis, those who used statins after a lung cancer diagnosis had a statistically nonsignificant 11 percent reduction in lung cancer-specific deaths. Among those who used at least 12 prescriptions of statins there was a statistically significant 19 percent reduction in lung cancer-specific deaths, and among those who used lipophilic statins such as simvastatin there was a 19 percent reduction in lung cancer-specific deaths as well.
Among all patients in the study, those who used statins in the year before a lung cancer diagnosis had a statistically significant 12 percent reduction in lung cancer-specific deaths.
Cardwell noted that the outcomes were not different between non-small cell lung cancer patients and small cell lung cancer patients in this study.
Cardwell said that the study provided some evidence that lung cancer patients who used statins had a reduction in the risk of death from lung cancer. The magnitude of the association was relatively small and, as with all observational studies, there was the possibility of confounding–meaning that simvastatin users may have differed from simvastatin nonusers in other ways that could have protected them from death from cancer, for which they couldn’t correct.
The study is published in Cancer Epidemiology, Biomarkers and Prevention. (ANI)